Saniye GİRİT1, Ayşe AYZIT ATABEK2, Ebru ŞENOL3, Tuba KOÇKAR KIZILIRMAK4, Sevgi PEKCAN5, Şafak GÖKTAŞ6, Sedat ÖKTEM4, Özgür KASAPÇOPUR7, Haluk ÇOKUĞRAŞ2

1Department of Pediatric Pulmonology, Medeniyet University Medical School Goztepe Training and Research Hospital, Istanbul, Turkey
2Department of Pediatric Pulmonology, Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey
3Department of Pediatrics, University of Health Sciences, Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
4Department of Pediatric Pulmonology, Medipol University Medical School, Istanbul, Turkey
5Department of Pediatric Pulmonology, Konya Necmettin Erbakan University Meram Medical School, Konya, Turkey
6Gelişim Medical Laboratories, Infectious Diseases and Microbiology, Istanbul, Turkey
7Department of Pediatric Rheumatology, Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey

Keywords: Child, immune system disease, interferon-gamma release assay, latent tuberculosis, tuberculin skin test

Abstract

Objectives: This study aims to analyze the coherence between T-SPOT tuberculosis test (T-SPOT.TB) and tuberculin skin test (TST) with different cut-off values in screening latent tuberculosis infection (LTBI) both prior to and at the sixth month of anti-tumor necrosis factor (anti-TNF) treatment.

Patients and methods: This prospective multicentric study included 57 children (34 girls, 23 boys, mean age 12.4±3.9 years; range, 6 to 18 years) diagnosed with immune-mediated inflammatory diseases (IMIDs) evaluated with TST and T-SPOT.TB for screening LTBI both prior to and at the sixth month of treatment with anti-TNF agents. Coherence between two tests was analyzed for TST cut-off values suggested by the local guidelines and also for different possible cut-off values of TST.

Results: Tuberculin skin test was positive (≥5 mm) in 28.1% (n=16) of patients in the screening prior to treatment and in 33.3% (n=19) at the sixth month of treatment. T-SPOT.TB test was positive in 8.8% (n=5) of patients both prior to and at the sixth month of treatment. Coherence between two tests was poor or fair when compared with all possible TST cut-off values both prior to and at the sixth month of anti-TNF therapy.

Conclusion: Our results show poor coherence between T-SPOT.TB and TST for all possible cut-off values of TST. Thus, using both tests would be beneficial in screening LTBI until further studies bring new evidence on the subject.